Cumulative C-reactive Protein in the Perioperative Period as a Novel Marker for Oncological Outcome in Patients with Colorectal Cancer Undergoing Curative Resection

Hiroyuki Fujikawa, Yoshinaga Okugawa, Akira Yamamoto, Hiroki Imaoka, Tadanobu Shimura, Takahito Kitajima, Mikio Kawamura, Hiromi Yasuda, Yoshiki Okita, Takeshi Yokoe, Masaki Ohi and Yuji Toiyama

Departments of Gastrointestinal and Pediatric Surgery, Division of Reparative Medicine, Institute of Life Sciences, Mie University Graduate School of Medicine, Tsu, Japan

Abstract

Objectives: Systemic inflammatory response is strongly associated with poor oncological outcome in colorectal cancer (CRC). Perioperative inflammation caused by surgical stress can lead to the development of postoperative infectious complications (PIC) as well as cancer-related inflammation. We aimed to evaluate the prognostic potential of perioperative systemic inflammation by calculating the time-dependent cumulative C-reactive protein (CRP) levels during the perioperative period.

Methods: We analyzed clinicopathological data from 540 patients with CRC who underwent potentially curative surgery at our institution. The time-dependent aggregated CRP level was denoted “cumulative CRP,” which represents the area under the line of time (days) and the CRP levels preoperatively and on postoperative days 1, 3, and 7.

Results: Cumulative CRP was significantly higher in patients with CRC undergoing open surgery than in patients undergoing laparoscopic surgery. In multivariate analysis, high cumulative CRP was an independent prognostic factor for disease-free survival (DFS) and overall survival (OS) in both the laparoscopic and open surgery groups. Patients with CRC and high cumulative CRP had significantly poorer DFS and OS than those with low cumulative CRP, including those patients without PIC.

Conclusions: Cumulative CRP is an independent predictive marker of OS and DFS in patients with CRC who undergo curative surgery.

Keywords
cumulative C-reactive protein, colorectal cancer, prognosis

Introduction

Colorectal cancer (CRC) is one of the most common malignant tumors worldwide[1]. Despite the development of radical surgery and multimodal therapies such as chemotherapy and chemoradiotherapy, the disease recurs in approximately 15%-30% of patients[2,3]. A major prognostic indicator for oncological outcome is the TNM classification, which is defined according to pathologic features[4]. Tumor-host interactions are mediated by a complex network of cytokines, chemokines, growth factors, and matrix remodeling enzymes that reach beyond the local tumor microenvironment and evoke systemic responses[5-7]. Recently, cancer-associated inflammation has been linked to the pathogenesis of many adult malignancies and is now recognized as the seventh “hallmark” of cancer[5]. Systemic inflammation is
most common in patients with poorly differentiated and advanced stage CRC; inflammation is also an independent factor of less favorable outcome[8-11]. Several preoperative inflammatory indexes such as the modified Glasgow Prognostic Score (mGPS) using C-reactive protein (CRP) and albumin[11], neutrophil to lymphocyte ratio[12], CRP to albumin ratio[13], and albumin to globulin ratio[14] have been associated with poor oncological outcome. In addition, previous studies have demonstrated an association between early postoperative inflammation status using CRP and neutrophil to lymphocyte ratio and poor oncological outcome[15-17]. For example, CRP levels on postoperative day 4 or the maximum CRP levels during the period from surgical resection to discharge were related to worse survival[16,17]. Postoperative inflammation is induced by surgical trauma and dynamically changes from day to day with postoperative infectious complications (PIC), such as surgical site infection (SSI) and remote infection (RI) in patients with CRC[18-20]. Therefore, preoperative inflammatory status, surgical stress, and development of PIC should be accurately evaluated as cumulative overall perioperative inflammation for predicting oncological outcome. We aimed to evaluate the prognostic potential of perioperative systemic inflammation using time-dependent aggregation of CRP levels from the preoperative period to postoperative day 7 in patients with CRC who undergo curative surgery.

**Methods**

**Patients**

We enrolled 540 patients who underwent potentially curative surgery for CRC at our institution between January 1, 2005, and December 31, 2015. Curative resection was defined as the absence of gross residual tumor in the surgical bed and a resection margin that was pathologically negative for tumor invasion. The patients were classified according to the TNM Classification of Union for International Cancer Control, 8th Edition. The patients granted their informed consent and were followed according to our standard protocol every 12-16 weeks. The protocol included tumor marker studies, computed tomography, endoscopic examination, ultrasonography, and chest radiography. This study was approved by the institutional review board of the Mie University Hospital.

**Clinical and laboratory data collection**

Data collected from inpatient and outpatient records included age and sex, tumor location (rectum or colon), neoadjuvant chemoradiotherapy (CRT), surgical procedure (open surgery or laparoscopic surgery), pathological characteristics (tumor staging, lymph node metastasis, tumor-cell differentiation, and lymphovascular invasion), carcinoembryonic antigen (CEA) levels at diagnosis, onset of PIC such as SSI and RI, disease-free survival (DFS), and overall survival (OS). All patients who were converted from laparoscopic surgery to open surgery were included in the open surgery group. OS was defined as the time from the date of surgery to the day of death from any cause. DFS was defined as the time from the date of surgery to the day of the first recurrence or death from any cause. PIC was defined as all SSI and RI that occurred within one month after surgery. CRP levels were quantified before surgery and at postoperative day (POD) 1, POD3, and POD7. The accumulated CRP level was denoted “cumulative CRP” and obtained by summing the area of each trapezoid calculated from the CRP levels preoperatively and at POD1, POD3, and 7 and time (days) (Figure 1). The cut-off value for CEA was 5 ng/mL, according to the normal range used in our hospital. The cut-off values for cumulative CRP were calculated in the open surgery and laparoscopic surgery groups separately, according to the receiver operating characteristic (ROC) curves for DFS. The cut-off values were defined as 57.8 and 24.1 in the open surgery and laparoscopic surgery groups, respectively.

**Statistical analysis**

Data are presented as mean ± standard deviation (SD). Comparisons were performed using the Mann-Whitney test. The optimal cut-off values of cumulative CRP were determined at the point on the ROC curve with the maximum Youden’s index (sensitivity + specificity − 1) for survival. Survival curves were generated using the Kaplan-Meier product-limit method, and comparisons were performed using the log-rank test. Prognostic factors were identified using univariate and multivariate analyses (Cox proportional-hazards regression model). All P-values were two-sided, and P < 0.05 was considered significant. All statistical analyses were performed using JMP 11 (SAS Institute Inc., Cary, NC, USA).

**Results**

**Patient characteristics**

This retrospective study included 321 male and 219 female patients with a median age of 68 years (range, 32-94 years). The number of patients undergoing laparoscopic and open surgery was 271 and 269, respectively. The median follow-up was 52.9 months (mean ± SD: 52.3 ± 33.8). Three (0.6%), 171 (31.7%), 187 (34.6%), and 179 (33.1%) patients had (yp)Stage 0, I, II, and III CRC, respectively. In total, 116 patients were treated with preoperative chemoradiotherapy; among them, 106 (19.6%) had disease recurrence after surgery with curative intent. Patients undergoing open surgery had a more advanced stage and PIC compared
Figure 1. Definition of cumulative C-reactive protein (CRP). Cumulative CRP is defined as the aggregate of perioperative CRP levels (i.e., preoperative, postoperative day (POD) 1, POD3, and POD7). The aggregate is calculated as the sum of the area of each trapezoid (a, b, c, and d).

Table 1. Patient Characteristics According to Surgical Procedure.

| Variables                      | Laparoscopic surgery (n = 271) | Open surgery (n = 269) | P-value |
|--------------------------------|--------------------------------|------------------------|---------|
| Age <68                        | 132                            | 142                    | 0.3431  |
| Age ≥68                        | 139                            | 127                    |         |
| Gender female                  | 121                            | 98                     | 0.0518  |
| Gender male                    | 150                            | 171                    |         |
| Serosal invasion               |                                |                        |         |
| T1 + 2 + 3                     | 258                            | 218                    | <0.0001 |
| T4                             | 13                             | 51                     |         |
| Lymph node metastasis absent   | 194                            | 166                    | 0.0149  |
| Lymph node metastasis present  | 77                             | 103                    |         |
| Histology well/mod             | 263                            | 234                    | 0.2731  |
| Histology por/muc              | 8                              | 35                     |         |
| Lymphatic invasion absent      | 124                            | 81                     | 0.0002  |
| Lymphatic invasion present     | 147                            | 188                    |         |
| Venous invasion absent         | 166                            | 138                    | 0.0197  |
| Venous invasion present        | 105                            | 131                    |         |
| Location colon                 | 173                            | 109                    | <0.0001 |
| Location rectum                | 98                             | 160                    |         |
| Chemoradiotherapy no           | 261                            | 163                    | <0.0001 |
| Chemoradiotherapy yes          | 10                             | 106                    |         |
| PIC absent                     | 234                            | 195                    | <0.0001 |
| PIC present                    | 37                             | 74                     |         |
| CEA ≤5 ng/mL                   | 178                            | 104                    | <0.0001 |
| CEA >5 ng/mL                   | 89                             | 134                    |         |

PIC, postinfectious complication; CEA carcinoembryonic antigen. Median age at surgery was 68 years in this cohort. Bold font indicates statistical significance.

with those undergoing laparoscopic surgery (Table 1).

Perioperative CRP levels and cumulative CRP in open and laparoscopic surgeries

The mean value of CRP at POD3 was highest during the perioperative period with measurement of CRP in both the open and laparoscopic surgery groups. Patients undergoing open surgery had significantly higher CRP levels than those undergoing laparoscopic surgery preoperatively and at POD 1, POD3, and POD7 (P < 0.0001; Table 2); cumulative CRP was significantly higher in patients undergoing open surgery than in those undergoing laparoscopic surgery (P < 0.0001; Table 2).
Table 2. Perioperative and Cumulative CRP Values in This Cohort.

| CRP (mg/dL)     | Laparoscopic surgery n = 271 (mean ± SD) | Open surgery n = 269 (mean ± SD) | P-value |
|-----------------|------------------------------------------|----------------------------------|---------|
| Preoperative    | 0.29 ± 0.88                              | 0.93 ± 2.49                      | <0.0001 |
| POD1            | 5.65 ± 3.27                              | 9.95 ± 5.09                      | <0.0001 |
| POD3            | 8.17 ± 5.87                              | 11.8 ± 6.84                      | <0.0001 |
| POD7            | 3.03 ± 4.1                               | 4.8 ± 5.44                       | <0.0001 |
| Cumulative CRP  | 38.9 ± 25.6                              | 59.9 ± 33.4                      | <0.0001 |

CRP, C-reactive protein; POD, postoperative day; SD, standard deviation. Bold font indicates statistical significance.

Table 3. Association between Clinicopathological Findings and Cumulative CRP in Patients in This Cohort.

| Variables             | Cumulative CRP (mean ± SD) | P-value | Cumulative CRP (mean ± SD) | P-value |
|-----------------------|-----------------------------|---------|-----------------------------|---------|
|                       | Laparoscopic surgery        |         | Open surgery                |         |
| Age                   |                             |         |                             |         |
| <68                   | 33.5 (±22.2)                | 0.0011  | 60.9 (±35.3)                | 0.8291  |
| ≥68                   | 44 (±27.5)                  |         | 58.9 (±31.1)                |         |
| Gender                |                             |         |                             |         |
| female                | 31.9 (±23.2)                | <0.0001 | 53.3 (±28.5)                | 0.018   |
| male                  | 44.5 (±26.1)                |         | 63.8 (±35.4)                |         |
| Serosal invasion      |                             |         |                             |         |
| T1 + 2 + 3           | 38.6 (±25.5)                | 0.4103  | 59.4 (±34.3)                | 0.2318  |
| T4                   | 44.3 (±27.3)                |         | 62.3 (±29.4)                |         |
| Lymph node metastasis|                             |         |                             |         |
| absent                | 38.5 (±25.8)                | 0.4449  | 57.4 (±31.5)                | 0.1721  |
| present              | 40 (±25.2)                  |         | 64.1 (±35.9)                |         |
| Histology             |                             |         |                             |         |
| well/mod              | 38.9 (±25.9)                | 0.4363  | 58.8 (±32)                  | 0.2731  |
| por/muc              | 40.2 (±13.5)                |         | 67.6 (±41)                  |         |
| Lymphatic invasion    |                             |         |                             |         |
| absent                | 39.1 (±27.3)                | 0.623   | 57 (±33.5)                  | 0.244   |
| present              | 38.7 (±24.1)                |         | 61.3 (±33.3)                |         |
| Venous invasion       |                             |         |                             |         |
| absent                | 39 (±26.1)                  | 0.924   | 59.6 (±31.8)                | 0.8373  |
| present              | 38.7 (±24.8)                |         | 60.4 (±35.1)                |         |
| Location              |                             |         |                             |         |
| colon                 | 42 (±25.3)                  | 0.0015  | 62.3 (±33.8)                | 0.302   |
| rectum                | 33.4 (±25.3)                |         | 58.4 (±33.1)                |         |
| Chemoradiotherapy     |                             |         |                             |         |
| no                    | 39 (±25.8)                  | 0.8211  | 57.9 (±29.9)                | 0.4626  |
| yes                   | 34.9 (±19.2)                |         | 63.2 (±37.9)                |         |
| PIC                   |                             |         |                             |         |
| absent                | 33.8 (±21.1)                | <0.0001 | 50.3 (±25.3)                | <0.0001 |
| present              | 70.8 (±28.6)                |         | 85.4 (±38.6)                |         |
| CEA                   |                             |         |                             |         |
| ≤5 ng/mL             | 37.3 (±25.2)                | 0.063   | 57.6 (±30.9)                | 0.4376  |
| >5 ng/mL             | 42.2 (±25.2)                |         | 62.8 (±36.1)                |         |

CEA, carcinoembryonic antigen; PIC, postinfectious complication; CRP, C-reactive protein; SD, standard deviation. Median age at surgery was 68 years in this cohort. Bold font indicates statistical significance.

Association between clinicopathological findings and cumulative CRP in open and laparoscopic surgery

The cumulative CRP was significantly higher in male patients and in those with PIC in both the laparoscopic (P < 0.0001, P < 0.0001, respectively) and open surgery groups (P = 0.018, P < 0.0001, respectively). By contrast, cumulative CRP was not associated with pathological status such as serosal invasion, lymph node metastasis, tumor grade, and lymphovascular invasion (Table 3).

Association between cumulative CRP and prognosis in patients with CRC who underwent open and laparoscopic surgery

We analyzed the association between cumulative CRP and prognosis according to open and laparoscopic surgery because operative stress differs between operative procedures. In both the open surgery and laparoscopic surgery groups (Figure 2), patients with high cumulative CRP had worse DFS and OS than those with low cumulative CRP (open surgery: P < 0.0001, P < 0.0001, respectively; laparoscopic surgery: P < 0.0001, P < 0.0001, respectively).
Figure 2. Analysis of the association of cumulative C-reactive protein (CRP) with survival in patients who underwent open or laparoscopic surgery in this cohort. Kaplan–Meier analysis of disease-free survival (DFS) and overall survival (OS) according to cumulative CRP in patients who underwent open (a: DFS, b: OS) or laparoscopic surgery (c: DFS, d: OS). The high cumulative CRP group had CRP levels higher than the cut-off value (open surgery: 57.8; laparoscopic surgery: 24.1). Both DFS and OS in the high cumulative CRP group were significantly lower than those in the low cumulative CRP group.

In the univariate analysis of open surgery, serosal invasion (T4), lymph node metastasis, lymphatic invasion, venous invasion, serum CEA levels (>5 ng/mL), PIC, and high cumulative CRP were associated with poor DFS (Table 4). Furthermore, lymph node metastasis, venous invasion, PIC, and high cumulative CRP were associated with poor OS (Table 4). In multivariate analysis, high cumulative CRP was an independent prognostic factor for both DFS (hazard ratio [HR]: 2.3, 95% confidence interval [CI] 1.44-3.73, P = 0.0005; Table 4) and OS (HR: 3.27, 95% CI 1.84-5.96, P < 0.0001; Table 4). In the univariate analysis of laparoscopic surgery, male sex, CRT, serosal invasion (T4), lymphatic invasion, venous invasion, and high cumulative CRP were associated with poor DFS (Table 5), and older age (>68 years), male sex, and high cumulative CRP were associated with poor OS (Table 5). In multivariate analysis, male sex and high cumulative CRP were independent prognostic factors for both DFS (HR: 2.49, 95% CI 1.1-6.7, P = 0.027; Table 5) and OS (HR: 5.71, 95% CI 1.14-103.8, P = 0.0303; Table 5).

Association between PIC and prognosis in patients with CRC

The cumulative CRP was significantly higher in patients with PIC in this cohort (Table 3). Therefore, we evaluated the association between PIC and prognosis in patients with CRC. In the survival analysis, the PIC group had significantly poorer prognosis than the non-PIC group for both DFS and OS (P < 0.0001, P < 0.0001, respectively; Figure 3).

Prognosis of patients with CRC without PIC, by cumulative CRP level

Next, we evaluated the association between prognosis and cumulative CRP in patients with CRC who did not have PIC. Patients with high cumulative CRP had significantly poorer DFS and OS than those with low cumulative CRP in
both the open (P = 0.0115, P = 0.0019, respectively; Figure 4a, 4b) and laparoscopic surgery groups (P = 0.0045, P = 0.0103, respectively; Figure 4c, 4d).

**Discussion**

The interaction between cancer cells and their microenvironment is considered to be an essential component of tumor progression and development of metastasis[21]. This microenvironment consists of inflammatory and immune cells and involves neutrophils and macrophages, carcinoma-associated fibroblasts, environmental conditions such as hypoxia, soluble factors, signaling molecules, and extracellular matrix components[22]. In cancer-bearing status, preoperative CRP reflects systemic inflammation induced by tumor-host interactions[8-10,23]. However, postoperative CRP usually reflects surgical stress and PIC as well as systemic inflammation induced by tumor-host interactions[19,20]. CRP is widely used as an early marker for detecting PICs. CRP levels increase after surgery, with a peak at 48 hours, after which time the values decrease in patients who do not experience postoperative complications[19]. In our study, patients with PIC had higher values of cumulative CRP and poorer prognosis than those without PIC. Several studies have shown that patients with PIC, such as anastomotic leakage and intraabdominal abscess, have poorer oncological prognosis than those without PIC[24,25]. Several hypotheses for the underlying mechanism are the implantation of tumor cells deposited extraluminally upon anastomotic leakage and apoptotic inhibition and proliferation of implanted cancer cells and occult metastasis caused by acute inflammatory response[26-28]. In addition, older patients are more likely to have a higher PIC rate. Therefore, PIC could be associated with poor survival from oncological and physiological standpoints.

Several reports support the hypothesis that the acute in-

---

**Table 4.** Cox Proportional-hazards Model Analysis for DFS and OS Predictors in Patients Who Underwent Open Surgery in This Cohort.

| DFS | Variables | Univariate HR (95% CI) | P-value | Multivariate HR (95% CI) | P-value |
|-----|-----------|------------------------|---------|--------------------------|---------|
| Age (≥68) | 1.19 (0.78–1.78) | 0.4178 | 1.19 (0.78–1.78) | 0.4178 |
| Gender (Male) | 0.98 (0.65–1.51) | 0.9302 | 0.98 (0.65–1.51) | 0.9302 |
| Tumor location (rectum) | 1.28 (0.84–2.01) | 0.252 | 1.28 (0.84–2.01) | 0.252 |
| Chemoradiotherapy (yes) | 0.72 (0.46–1.09) | 0.1234 | 0.72 (0.46–1.09) | 0.1234 |
| Histology (por/muc) | 0.99 (0.53–1.72) | 0.9745 | 0.99 (0.53–1.72) | 0.9745 |
| Serosal invasion (T4) | 2.35 (1.49–3.62) | **0.0004** | 1.54 (0.95–2.45) | 0.0789 |
| Lymph node metastasis (positive) | 2.67 (1.77–4.06) | **<0.0001** | 2.07 (1.31–3.31) | **0.0019** |
| Lymphatic invasion (positive) | 1.79 (1.12–3.02) | **0.0148** | 0.97 (0.55–1.76) | 0.9143 |
| Venous invasion (positive) | 2.17 (1.43–3.36) | **0.0003** | 1.51 (0.92–2.52) | 0.1052 |
| CEA (>5) | 1.82 (1.18–2.88) | **0.0007** | 1.35 (0.88–2.24) | 0.2075 |
| PIC (yes) | 2.26 (1.48–3.41) | **0.0002** | 1.41 (0.88–2.24) | 0.1493 |
| Cumulative CRP (>57.8) | 2.43 (1.6–3.73) | **<0.0001** | 2.3 (1.44–3.73) | **0.0005** |

| OS | Variables | Univariate HR (95% CI) | P-value | Multivariate HR (95% CI) | P-value |
|-----|-----------|------------------------|---------|--------------------------|---------|
| Age (≥68) | 1.48 (0.88–2.46) | 0.1407 | 1.48 (0.88–2.46) | 0.1407 |
| Gender (Male) | 1.05 (0.63–1.81) | 0.8557 | 1.05 (0.63–1.81) | 0.8557 |
| Tumor location (rectum) | 1.22 (0.72–2.15) | 0.473 | 1.22 (0.72–2.15) | 0.473 |
| Chemoradiotherapy (yes) | 0.67 (0.39–1.13) | 0.138 | 0.67 (0.39–1.13) | 0.138 |
| Histology (por/muc) | 1.29 (0.62–2.44) | 0.4686 | 1.29 (0.62–2.44) | 0.4686 |
| Serosal invasion (T4) | 1.73 (0.93–3.03) | 0.0798 | 1.73 (0.93–3.03) | 0.0798 |
| Lymph node metastasis (positive) | 1.78 (1.07–2.95) | **0.0266** | 1.43 (0.84–2.46) | 0.1802 |
| Lymphatic invasion (positive) | 1.69 (0.94–3.25) | 0.0795 | 1.69 (0.94–3.25) | 0.0795 |
| Venous invasion (positive) | 1.9 (1.13–3.27) | **0.0143** | 1.89 (1.09–3.36) | **0.0217** |
| CEA (>5) | 1.48 (0.86–2.61) | 0.1544 | 1.48 (0.86–2.61) | 0.1544 |
| PIC (yes) | 2.57 (1.53–4.26) | **0.0005** | 1.59 (0.91–2.72) | 0.0964 |
| Cumulative CRP (>57.8) | 3.48 (2.05–6.14) | **<0.0001** | 3.27 (1.84–5.96) | **<0.0001** |

DFS, disease-free survival; OS, overall survival; CEA, carcinoembryonic antigen; PIC, postinfectious complication; CRP, C-reactive protein; HR, hazard ratio; CI, confidence interval. Median age at surgery was 68 years in this cohort. Bold font indicates statistical significance.
**Table 5.** Cox Proportional-hazards Model Analysis for DFS and OS Predictors in Patients Who Underwent Laparoscopic Surgery in This Cohort.

### DFS

| Variables                  | Univariate HR (95% CI) | P-value | Multivariate HR (95% CI) | P-value |
|----------------------------|------------------------|---------|--------------------------|---------|
| Age (≥68)                  | 1.06 (0.57–1.94)       | 0.8623  | 2.69 (1.26–6.48)         | 0.0098  |
| Gender (Male)              | 3.75 (1.83–8.73)       | **0.0002** | 2.69 (1.26–6.48)         | **0.0098** |
| Tumor location (rectum)   | 1.49 (0.79–2.74)       | 0.2056  |                         |         |
| Chemoradiotherapy (yes)    | 4.43 (1.52–10.4)       | **0.0095** | 6.45 (2.13–16)           | **0.0023** |
| Histology (por/muc)        | 0.71 (0.04–3.26)       | 0.7194  |                         |         |
| Serosal invasion (T4)      | 3.51 (1.21–8.17)       | **0.0243** | 2.01 (0.67–4.89)         | 0.1932  |
| Lymph node metastasis (positive) | 1.75 (0.93–3.21) | 0.0834  |                         |         |
| Venous invasion (positive) | 3.29 (1.65–7.33)       | **0.0053** | 2.98 (1.37–7.09)         | **0.0053** |
| CEA (>5)                   | 0.89 (0.45–1.69)       | 0.7388  |                         |         |
| PIC (yes)                  | 1.19 (0.48–2.52)       | 0.6786  |                         |         |
| Cumulative CRP (>24.1)     | 3.34 (1.51–8.83)       | **0.0018** | 2.49 (1.1–6.7)           | **0.027** |

### OS

| Variables                  | Univariate HR (95% CI) | P-value | Multivariate HR (95% CI) | P-value |
|----------------------------|------------------------|---------|--------------------------|---------|
| Age (≥68)                  | 3.17 (1.21–9.82)       | **0.0177** | 2.85 (1.08–8.86)         | **0.033** |
| Gender (Male)              | 4.9 (1.63–21.1)        | **0.0033** | 3.75 (1.23–16.2)         | **0.0177** |
| Tumor location (rectum)   | 1.04 (0.36–2.69)       | 0.9351  |                         |         |
| Chemoradiotherapy (yes)    | n.a.                   | 0.3295  |                         |         |
| Histology (por/muc)        | n.a.                   | 0.2529  |                         |         |
| Serosal invasion (T4)      | 1.34 (0.07–6.58)       | 0.7834  |                         |         |
| Lymph node metastasis (positive) | 1.45 (0.54–3.62) | 0.4425  |                         |         |
| Venous invasion (positive) | 1.77 (0.7–5.05)        | 0.2324  |                         |         |
| CEA (>5)                   | 1.35 (0.52–3.38)       | 0.5236  |                         |         |
| PIC (yes)                  | 1.55 (0.59–3.84)       | 0.3543  |                         |         |
| Cumulative CRP (>24.1)     | 8.96 (1.85–161.3)      | **0.0029** | 5.71 (1.14–103.8)        | **0.0303** |

DFS, disease-free survival; OS, overall survival; CEA, carcinoembryonic antigen; PIC, postinfectious complication; CRP, C-reactive protein; HR, hazard ratio; CI, confidence interval; n.a. not available. Median age at surgery was 68 years in this cohort. Bold font indicates statistical significance.

**Figure 3.** Analysis of the association of postoperative infectious complications (PIC) with survival and cumulative CRP among all patients in this cohort. Kaplan–Meier analysis of disease-free survival (DFS) (a) and overall survival (OS) (b) according to PIC. Both DFS and OS in the PIC group were significantly lower than those in the non-PIC group.
Inflammatory response to surgery promotes cancer metastasis, e.g., by stimulating the adhesion of viable circulating cancer cells to the endothelial cell layer owing to proinflammatory cytokines, exposing the underlying extracellular matrix with which the cancer cells can interact, and accelerating development of new metastatic disease through formation of neutrophil extracellular traps[29-32]. Postoperative inflammation is considered to be induced by surgical stress, PIC, and tumor-host interaction. Hence, we assume that the integration of perioperative CRP might more accurately reflect whole inflammation response in the perioperative period compared to one-day CRP, especially when evaluating the inflammatory response of surgical stress and tumor-host interaction. According to the ROC curves, the AUCs of cumulative CRP levels were almost superior or equivalent to the AUCs of each timepoint CRP level, though each AUC was not significantly different (data not shown). Therefore, we designed cumulative CRP as the integration of perioperative CRP. In this study, we evaluated the association between cumulative CRP and oncological outcome in patients with CRC but without PIC. In addition, the high cumulative CRP group had a roughly worse prognosis compared to the low cumulative CRP group in each stage (data not shown). The results showed that patients with higher cumulative CRP had poorer prognosis than those with lower cumulative CRP in both the laparoscopic and open surgery groups, which indicates that the degree of surgical stress might also be a risk factor of poor oncological outcome.

In our study, the group that underwent laparoscopic surgery had lower values of cumulative CRP than that who had open surgery. Most studies also report lower postoperative CRP values with laparoscopic surgery than with open surgery[33]. The lower inflammatory response in laparoscopic surgery compared with open surgery indicates that the laparoscopic procedure is a minimally invasive surgery and is more beneficial to the patient recovery than the conventional open procedure. However, previous randomized controlled trials demonstrated that laparoscopic surgery for CRC did
not differ significantly from open surgery in oncological outcome[34]. Therefore, we hypothesized that the relative inflammatory response in each surgical approach might be associated with oncological outcome and evaluated the association between cumulative CRP and oncological outcome in patients that underwent laparoscopic surgery and open surgery separately. Interestingly, despite the lower surgical stress following laparoscopic surgery, patients with CRC who had higher cumulative CRP values had poorer outcomes than their counterparts.

In this study, high levels of cumulative CRP were an independent prognostic factor for both DFS and OS, although cumulative CRP was not associated with tumor progression factors such as serosal invasion, lymph node metastasis, tumor grade, and lymphovascular invasion. This result shows that perioperative systemic inflammation could worsen long-term outcome after surgery, regardless of the tumor malignant potential. Collectively, cumulative CRP could be a risk factor that is useful in evaluation of aggressive disease as well as conventional tumor staging.

This study has several limitations as this was a single-center, retrospective study with a small sample size. To overcome these limitations, multi-institutional prospective studies with a large sample size are needed.

In conclusion, this is the first study to show that cumulative CRP, which reflects perioperative systemic inflammation caused by surgical stress and PIC, is an independent predictive marker of OS and DFS in patients with CRC who undergo curative surgery. Our findings support that the aggressiveness of perioperative inflammation has a negative impact on oncological outcome in CRC.

Acknowledgements
We thank Analisa Avila, ELS, of the Edanz Group (https://en-author-services.edanzgroup.com/ac) for editing a draft of this manuscript.

Conflicts of Interest
There are no conflicts of interest.

Author Contributions
HF drafted the manuscript. HF, AY, HI, TS, TK, MK, HY, YOki, TY, and MO contributed to the collection. HF and YOki analyzed and interpreted the data. HF, YOki, and YT conceived and designed the study. YT edited the manuscript. All authors approved the final manuscript.

Approval by Institutional Review Board (IRB)
The present study was reviewed and approved by the Mie University Institutional Review Board (No. 3203). This study was performed in accordance with the Declaration of Helsinki.

Informed Consent
This project was a retrospective observational study. We offered an opt-out for participants to provide the opportunity to reject participation in the study.

References
1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov; 68(6): 394-424.
2. Faby BN. Follow-up after curative resection of colorectal cancer. Ann Surg Oncol. 2014 Mar; 21(3): 738-46.
3. Kobayashi H, Mochizuki H, Sugihara K, et al. Characteristics of recurrence and surveillance tools after curative resection for colorectal cancer: a multicenter study. Surgery. 2007 Jan; 141(1): 67-75.
4. Amin M.B., Edge S, Greene F, et al. AJCC Cancer staging manual. 8th ed. New York: Springer International; 2017.
5. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011 Mar; 144(5): 646-74.
6. Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance. J Cell Sci. 2012 Dec; 125(23): 5591-6.
7. McAllister SS, Weinberg RA. The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis. Nat Cell Biol. 2014 Aug; 16(8): 717-27.
8. Kantola T, Klintrup K, Varyeny JP, et al. Stage-dependent alterations of the serum cytokine pattern in colorectal carcinoma. Br J Cancer. 2012 Nov 6; 107(10): 1729-36.
9. Park JH, Watt DG, Roxburgh CS, et al. Colorectal cancer, systemic inflammation, and outcome: staging the tumor and staging the host. Ann Surg. 2016 Feb; 263(2): 326-36.
10. Pathak S, Nunes QM, Daniels IR, et al. C-reactive protein useful in prognostication for colorectal cancer? A systematic review. Colorectal Dis. 2014 Oct; 16(10): 769-76.
11. McMillan DC. The systemic inflammation-based Glasgow prognostic score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013 Aug; 39(5): 534-40.
12. Hara Y, Boland MR, Kelly ME, et al. The prognostic value of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review. J Surg Oncol. 2017 Mar; 115(4): 470-9.
13. Zhou QP, Li XJ. C-reactive protein to albumin ratio in colorectal cancer: a meta-analysis of prognostic value. Dose Response. 2019 Nov; 17(4): 1559325819889814.
14. Nazha B, Moussaly E, Zaourr M, et al. Hypoalbuminemia in colorectal cancer prognosis: nutritional marker or inflammatory surrogate? World J Gastrointest Surg. 2015 Dec; 7(12): 370-7.
15. Hayama T, Hashiguchi Y, Okada Y, et al. Significance of the 7th postoperative day neutrophil-to-lymphocyte ratio in colorectal cancer. Int J Colorectal Dis. 2020 Jan; 35(1): 119-24.
16. McSorley ST, Watt DG, Horgan PG, et al. Postoperative systemic inflammatory response, complication severity, and survival following surgery for colorectal cancer. Ann Surg Oncol. 2016 Sep; 23 (9): 2832-40.
17. Matsubara D, Arita T, Nakanishi M, et al. The impact of postoperative inflammation on recurrence in patients with colorectal cancer. Int J Clin Oncol. 2020 Apr; 25(4): 602-13.
18. Facy O, Paquette B, Orry D, et al. Inflammatory markers as early predictors of infection after colorectal surgery: the same cut-off
values in laparoscopy and laparotomy? Int J Colorectal Dis. 2017 Jun; 32(6): 857-63.

19. Straatman J, Cuesta MA, Tuynman JB, et al. C-reactive protein in predicting major postoperative complications are there differences in open and minimally invasive colorectal surgery? Substudy from a randomized clinical trial. Surg Endosc. 2018 Jun; 32(6): 2877-85.

20. Cabellos Olivares M, Labalde Martinez M, Torralba M, et al. C-reactive protein as a marker of the surgical stress reduction within an ERAS protocol (Enhanced Recovery After Surgery) in colorectal surgery; a prospective cohort study. J Surg Oncol. 2018 Mar; 117(4): 717-24.

21. Pretzsch E, Bosch F, Neumann J, et al. Mechanisms of metastasis in colorectal cancer and metastatic organotropism: hematogenous versus peritoneal spread. J Oncol. 2019 Sep; 2019: 7407190.

22. Mariani F, Sena P, Roncucci L. Inflammatory pathways in the early steps of colorectal cancer development. World J Gastroenterol. 2014 Aug; 20(29): 9716-31.

23. Park JH, van Wyk H, Roxburgh CSD, et al. Tumour invasiveness, the local and systemic environment and the basis of staging systems in colorectal cancer. Br J Cancer. 2017 May; 116(11): 1444-50.

24. Shimada H, Fukagawa T, Haga Y, et al. Does postoperative morbidity worsen the oncological outcome after radical surgery for gastrointestinal cancers? A systematic review of the literature. Ann Gastroenterol Surg. 2017 Apr; 1(1): 11-23.

25. Sueda T, Tei M, Yoshikawa Y, et al. Prognostic impact of postoperative intra-abdominal infections after elective colorectal cancer resection on survival and local recurrence: a propensity score-matched analysis. Int J Colorectal Dis. 2020 Mar; 35(3): 413-22.

26. Merkel S, Wang WY, Schmidt O, et al. Locoregional recurrence in patients with anastomotic leakage after anterior resection for rectal carcinoma. Colorectal Dis. 2001 May; 3(3): 154-60.

27. Mirnezami A, Mirnezami R, Chandrakumaran K, et al. Increased local recurrence and reduced survival from colorectal cancer following anastomotic leak: systematic review and meta-analysis. Ann Surg. 2011 May; 253(5): 890-9.

28. Alonso S, Pascual M, Salvans S, et al. Postoperative intra-abdominal infection and colorectal cancer recurrence: a prospective matched cohort study of inflammatory and angiogenic responses as mechanisms involved in this association. Eur J Surg Oncol. 2015 Feb; 41(2): 208-14.

29. Tohme S, Simmons RL, Tsung A. Surgery for cancer: a trigger for metastases. Cancer Res. 2017 Apr; 77(7): 1548-52.

30. van der Bij GJ, Oosterling SJ, Beelen RH, et al. The perioperative period is an underutilized window of therapeutic opportunity in patients with colorectal cancer. Ann Surg. 2009 May; 249(5): 727-34.

31. Oosterling SJ, van der Bij GJ, Bogels M, et al. Anti-beta1 integrin antibody reduces surgery-induced adhesion of colon carcinoma cells to traumatized peritoneal surfaces. Ann Surg. 2008 Jan; 247(1): 85-94.

32. Tohme S, Yazdani HO, Al-Khafaji AB, et al. Neutrophil extracellular traps promote the development and progression of liver metastases after surgical stress. Cancer Res. 2016 Mar; 76(6): 1367-80.

33. Novitsky YW, Litwin DE, Callery MP. The net immunologic advantage of laparoscopic surgery. Surg Endosc. 2004 Oct; 18(10): 1411-9.

34. Wang CL, Qu G, Xu HW. The short- and long-term outcomes of laparoscopic versus open surgery for colorectal cancer: a meta-analysis. Int J Colorectal Dis. 2014 Mar; 29(3): 309-20.